Pharmacogenetics and pharmacogenomics are areas of significant importance at the interface of molecular genetics and psychopharmacology, with implications for drug development and clinical practice. This 2002 book provides a conceptual framework for understanding and studying the pharmacogenetics of psychotropic drugs, reviews advances in the field, and describes the established findings. Coverage extends to antipsychotics, antidepressants, mood stabilising, cognitive-enhancing and anxiolytic drugs. Chapters also examine the interface of pharmacogenetics with substance dependence and brain imaging, and consider its impact on the biotechnology and pharmaceutical industries. This book defines the young field of pharmacogenetics as it applies to psychotropic drugs, and is therefore of interest to all clinicians and researchers working in this field.
This book addresses the basic and advanced knowledge on psychiatric disorders for non-clinicians. The volume compiles in-depth information on the psychopharmacogenetic, representing an important area of research that is based on various specialties including clinical psychiatry, pharmacology, neurobiology and genetics. The book also addresses questions related to the field of psychiatric disorders that are not usually addressed in one work. The questions considered include: What is schizophrenia? What are the risk factors? What are the core symptoms? How is it treated? What are the efficacy and side effects of the available treatments?
Publisher: Karger Medical and Scientific Publishers
In recent years, there have been major developments in the fields of pharmacogenetics and pharmacogenomics, with the potential to make drug treatments in psychiatric medicine more effective. However, improvements in drug efficacy and tolerability, as well as finding the optimal dosage, can only be realized if in vivo mechanisms of drug action and ADME (absorption, distribution, metabolism, excretion) processes (pharmacokinetics) of psychopharmacological agents are better understood. In this volume, current progress and perspectives in pharmacogenetic testing of drug-metabolizing enzymes, drug transporters and other drug targets involved in the response to psychotropic agents are described extensively. This provides a timely overview of what has been achieved in the area of psychiatric pharmacogenomics alongside some promising directions and perspectives for future research.Psychiatrists, general medical doctors as well as pharmacologists and clinical pharmacologists will find new insights into the development and applications of pharmacogenomics in psychiatry.
Information about new psychotropic drugs, a summary of advances in knowledge about identifiable risk factors for adverse effects, and updated recommendations on viable "antidote" management strategies -- including novel pharmacotherapies for tardive dyskinesia and newer agents for weight loss -- are among the features of this new, second edition of Managing the Side Effects of Psychotropic Medications. Where other psychopharmacology textbooks -- and, indeed, most internships and residencies in psychiatry -- lack a solid basis in primary care medicine, this guide bridges that educational gap, offering a thorough examination of all the effects of taking a psychotropic drug as well practical clinical advice on how to manage complications that arise. The book is divided into three parts: The first deals with global issues that affect the assessment and formulation of possible adverse effects, as well as with pertinent concepts related to basic pharmacology, physiology, and medical monitoring. The second part presents information organized by individual organ systems or specific medical circumstances. The final part focuses on summary recommendations covering all the material presented in the book and is followed by helpful appendixes and self-assessment questions and resources for practitioners. This new edition includes: Updated summaries about what psychiatrists should know regarding drug-drug interactions, iatrogenic cardiac arrhythmias, drug pressor effects and orthostatic hypotension, and drug rashes; as well as updated discussions on avoiding lithium nephrotoxicity, handling adverse effect emergencies, and understanding new FDA classifications about drug safety during pregnancy An expanded discussion on the strengths and limitations of pharmacogenetic testing to predict adverse drug effects, as well as information about new treatments for sexual dysfunction, sleep disturbances, cognitive complaints, and other maladies Revised summary tables to aid rapid assessment and management An expanded section on supplemental resources An updated and expanded self-assessment section with more key questions Busy clinicians will find in Managing the Side Effects of Psychotropic Medications an accessible reference that provides both scientific and scholarly discussion of the consequences of drug therapies they may prescribe (or avoid), the range of available strategies to effectively manage adverse effects, and the scientific and practical implications of their treatment decisions.
First comprehensive book on pharmacogenomics - a new and innovative discipline to revolutionize health care! Pharmacogenomics leads to the understanding of the key genetic differences between individuals and will permit individual tailoring of pharmacological treatments. Improved therapeutics can reach new levels by being able to differentiate between individuals according to their predisposition to disease processes or susceptibility to adverse effects of medications. Outstanding experts in the field present an overview of the state-of-the-art of this young and promising approach and provide insight into the recent findings for all relevant disease classes. The book is indispensable for a wide audience of individuals working in the various areas that contribute to this field such as pharmacology, genetics, molecular biology, pharmaceutics, medicinal chemistry and clinical medicine.
This volume features thorough reviews by active clinicians and researchers of drug metabolizing reactions which show genetic variability between humans. This includes the molecular and biochemical aspects of key enzymes and the pharmacological consequences. Also included are selected epidemiological and methodological topics intended to be of use to researchers pursuing further investigation in this field.
Univ. of Illinois, Chicago. Pocket-sized text provides expanded coverage of more than 80 polymorphic genes that influence drug disposition and sensitivity. Edition includes exclusive updates on key polymorphisms in drug therapy decision-making. Listed alphabetically by drug and brand name. Thumb-tabbed. Previous edition: c2003. Softcover.
Principles of Psychopharmacology for Mental Health Professionals addresses the current "split" model of mental health that combines the care of a pysician who delivers pharmacotherapy with the care of a mental health professional. This book is intended to familiarize mental health professionals with the drugs used to treat mental illness so they can recognize side effects of treatment and provide better care for their patients.
Interdisciplinary in its coverage of drug issues, this comprehensive text examines drug use and abuse from historical, cultural, social, psychological, biological, and medical perspectives. The third edition features enhanced coverage of substance abuse prevention and treatment and includes discussion of many contemporary issues. The author's explanatory writing style enables all levels of students to understand the sometimes difficult concepts presented in the text.